IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. 
Magnesium Treatment in Hypoparathyroidism
This study has been completed.
Sponsor:
University of Tartu
Information provided by (Responsible Party):
Vallo Volke, University of Tartu
ClinicalTrials.gov Identifier:
NCT00824226
First received: January 15, 2009
Last updated: August 26, 2011
Last verified: August 2011
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Study hypothesis: supplementary magnesium may influence the blood calcium level in treated hypoparathyroid patients. Patients will be treated with supplementary magnesium (350 mg/day) for 3 weeks. Calcium and other relevant blood parameters will be measured before the treatment, at the end of treatment and 2 weeks after stopping treatment.
| Condition | Intervention |
|---|---|
| Hypoparathyroidism | Dietary Supplement: magnesium |
| Study Type: | Interventional |
| Study Design: | Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Treatment |
| Official Title: | Effect of Magnesium Treatment on Plasma Calcium in Hypoparathyroid Patients |
Resource links provided by NLM:
Further study details as provided by Vallo Volke, University of Tartu:
Primary Outcome Measures:
- Calcium level at the end of magnesium treatment compared to pretreatment level [ Time Frame: 3 weeks ]
Secondary Outcome Measures:
- Calcium level after stopping treatment compared to the level at the end of magnesium treatment [ Time Frame: 2 weeks ]
| Enrollment: | 10 |
| Study Start Date: | January 2009 |
| Study Completion Date: | August 2011 |
| Primary Completion Date: | August 2011 (Final data collection date for primary outcome measure) |
Intervention Details:
-
Dietary Supplement: magnesium
magnesium 350 mg tablets once a day for 3 weeks
Eligibility| Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- primary or secondary hypoparathyroidism
- treatment with calcium plus vitamin D analogue
- ionized calcium 1,0-1,29 mmol/L
- magnesium level 0,7-1,05 mmol/L
- TSH 0.1- 10 imU/L
Exclusion Criteria:
- any other disease known to influence plasma Ca level
- pregnancy
- creatinine > 150 microM/L
- patient has used supplementary magnesium within 2 previous months
Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00824226
Please refer to this study by its ClinicalTrials.gov identifier: NCT00824226
Locations
| Estonia | |
| Tartu University Hospital | |
| Tartu, Estonia, 50406 | |
Sponsors and Collaborators
University of Tartu
Investigators
| Principal Investigator: | Vallo Volke, MD, PhD | University of Tartu, Institute of Physiology |
More Information
| Responsible Party: | Vallo Volke, Dr., University of Tartu |
| ClinicalTrials.gov Identifier: | NCT00824226 History of Changes |
| Other Study ID Numbers: |
UT296 |
| Study First Received: | January 15, 2009 |
| Last Updated: | August 26, 2011 |
Keywords provided by Vallo Volke, University of Tartu:
|
primary hypoparathyroidism secondary hypoparathyroidism magnesium |
Additional relevant MeSH terms:
|
Hypoparathyroidism Parathyroid Diseases Endocrine System Diseases |
ClinicalTrials.gov processed this record on September 19, 2017